We measured the expression of BTG3 mRNA in ovarian normal tissue (n = 17), benign tumor (n = 12), borderline tumor (n = 6), and primary (n = 65) and metastatic carcinoma (n = 21) by real-time RT–PCR. This evidence concerns the gene BTG3 and metastatic carcinoma.